Jesus Fabregas Mercado, MD, MPH

Hematology & Oncology
Accepting New Patients

Memorial Cancer Institute

1750 East Hallandale Beach Boulevard
Hallandale, FL 33009



Get Directions

Memorial Cancer Institute

1150 North 35th Avenue Suite 330
Hollywood, FL 33021



Get Directions

About Me

I am a medical oncologist at Memorial Cancer Institute where I specialize in treating patients with gastrointestinal malignancies: colon cancer, rectal cancer, esophageal cancer, gastric cancer, hepatocellular carcinoma, cholangiocarcinoma, pancreatic cancer, anal cancer and neuroendocrine tumors. I am board certified in Medical Oncology, Hematology and Internal Medicine.

For me, providing cancer care is not work, it is a passion. I find great joy and purpose in helping patients through one of the most difficult times in their lives.

I aim to improve each patient’s quality of life and provide personalized care by accessing the latest targeted and immunotherapy treatments through clinical trials. I am involved in phase I, II and III trials, and share my research learnings through publications, presentations and collaborating with other oncology professionals around the world.

In addition to medical training, I also completed a Master of Public Health degree in Epidemiology from Harvard University – Harvard TH Chan School of Public Health. My research evaluated inequities and the impact of social determinants of health in cancer care in the US.

I also publish about disparities in patients with pancreatic cancer and have presented my research at several oncology society meetings including American Society of Clinical Oncology (ASCO), American Society of Hematology (ASH) and European Society of Medical Oncology – GI (ESMO-GI). I’m also a reviewer for the journal Frontiers in Oncology. I am involved in clinical trial design as part of the NRG colon cancer core committee, and I’m a Fellow of the American College of Physicians.

Before joining Memorial Cancer Institute, I was an Assistant Professor of Medicine in the Division of Hematology Oncology at the University of Florida College of Medicine where I focused on patients with colorectal malignancies.



Harvard T.H. Chan-School of Public Health, 2021
Universidad Del Norte, 2003


University of Miami - Jackson Memorial Hospital - Internal Medicine Prog, 2012, Internal Medicine


University of Miami - Jackson Memorial Hospital - Internal Medicine Prog, 2012, Internal Medicine


University of Miami - Jackson Hospital - Oncology and Hematology Fellowship, 2015, Oncology and Hematology


American Board of Internal Medicine-Hematology
American Board of Internal Medicine-Internal Medicine
American Board of Internal Medicine-Medical Oncology

Awards, Achievements, and More


Please view Dr. Jesus C. Fabregas publications on PubMed.


My research endeavors included a meta-analysis studying the feasibility of minimizing toxicities in patients with early rectal cancer, and refining prognosis and treatment selection for patients with early colon cancer applying a machine-learning model.

Recenter research projects where I served as local principal investigator include:

  • 2022 – NCT05174169 Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US)

  • 2019 - NCT03703297 Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)

  • 2019 - NCT03829332 A Phase 3, randomized, double-blind trial of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) in participants with treatment-naïve, metastatic non-small cell lung cancer (NSCLC) whose tumors have a tumor proportion score (TPS) greater than or equal to 1%(LEAP-007)

  • 2019 - NCT03294083 A Phase 1b Dose-escalation Study of Pexa-Vec (Thymidine Kinase Deactivated Vaccinia Virus plus GM-CSF) in Combination with REGN2810 (anti-PD-1) in Patients with Metastatic or Unresectable Renal Cell Carcinoma (RCC)

  • 2019 - NCT03448978 Phase I Safety and Feasibility Study of Autologous CD8+ T-cells Transiently Expressing a Chimeric Antigen Receptor Directed to B-Cell Maturation Antigen in Patients with Multiple Myeloma

  • 2018 - NCT03452137 A Study of Atezolizumab (Anti−Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck

  • 2018 - NCT03033511 A Randomized, Double Blind, Placebo Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First Line Platinum Based Chemotherapy in Subjects with Extensive Stage Small Cell Lung Cancer (MERU)

  • 2018 - NCT03365791 PDR 001 Plus LAG525 For Patients with Advanced Solid and Hematologic Malignancies

Professional Organizations

  • American Society of Clinical Oncology (ASCO)
  • American College of Physicians (ACP)
  • Florida Society of Clinical Oncology (FLASCO)
  • NRG Oncology


  • Importance Order of Risk Factors for Mortality in Colon Cancer Stage II: A Multivariate Adaptive Regression Spline (MARS) Analysis, Annals of Oncology Volume 32, supplement 3, 2021. Oral virtual presentation at ESMO GI World Congress 2021. Barcelona, Spain.

  • Sherise C. Rogers, Shu Wang, Ryan Michael Thomas, Brian Hemendra Ramnaraign, Jesus C. Fabregas, Ilyas Sahin, Stephen Staal, Martina Cathryn Murphy, Anna Melissa Singson Murillo, Merry Jennifer Markham, Frederic J. Kaye, Coy D. Heldermon, Dennie V. Jones, Nam H. Dang, Julia Lee Close, Thomas J. George, Carmen Joseph Allegra. A phase II randomized therapeutic optimization trial for subjects with refractory metastatic colorectal cancer using circulating tumor DNA (ctDNA): Rapid 1 trial. Poster presentation ASCO GI. San Francisco. January 2022.

  • Thomas J. George, Greg Yothers, Samuel A. Jacobs, Gene Grant Finley, James Lloyd Wade, Caio Max Sao Pedro Rocha Lima, Jeffrey Scott Rose, Shalu Pahuja, Anuradha Krishnamurthy, John C. Krauss, Melvin Deutsch, Jesus C. Fabregas, James J. Lee, Carmen Joseph Allegra, Norman Wolmark. Phase II study of durvalumab following neoadjuvant chemoRT in operable rectal cancer: NSABP FR-2. Poster presentation ASCO GI. San Francisco. January 2022.

  • Brian Hemendra Ramnaraign, Ji-Hyun Lee, azka ali, Sherise C. Rogers, Jesus C. Fabregas, Ryan M. Thomas, Carmen Joseph Allegra, Ilyas Sahin, David L. DeRemer, Thomas J. George, Jonathan Alexander Chatzkel. A phase Ib/II study (IMMCO-1) of atezolizumab plus tivozanib in immunologically cold pancreatic, gallbladder and biliary cancers. Poster presentation ASCO GI. San Francisco. January 2022.

  • Sherise C. Rogers, Ji-Hyun Lee, Brian Hemendra Ramnaraign, Kathryn Hitchcock, Steven J. Hughes, Anita Ahmed Turk, Karen Bullock Russell, Ahmad El-Far, Ryan M. Thomas, Jesus C. Fabregas, Ilyas Sahin, Carmen Joseph Allegra, David L. DeRemer, Thomas J. George. A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study. Poster presentation ASCO GI. San Francisco. January 2022.


  • 2015 Peter A. Cassileth, M.D. Award University of Miami Miller School of Medicine Division of Hematology Oncology, Presented to a Fellow with Outstanding Clinical Judgement and Compassion Miami, FL.
  • 2014 American Society of Hematology Advocacy Leadership Institute Elected to represent ASH in advocacy efforts at the Congress in Washington, DC.
  • 2012 American College of Physicians (ACP) Outstanding Resident Award University of Miami – American College of Physicians Miami, FL.
  • 2011 National Winner – Poster Presentation ACP Internal Medicine Meeting San Diego, CA. 2010 1st Place ACP Scientific Meeting, Oral Presentation Fort Lauderdale, FL.